Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: A randomized double-blind study

International Clinical Psychopharmacology

Volumn 16, Issue 6, 2001, Pages 325-330

  Zhang, Xiang Yang ^a,b,c   Zhou, D F ^a   Cao, L Y ^b   Zhang, P Y ^d   Wu, G Y ^d   Shen, Y C ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b BEIJING HUILONGGUAN HOSPITAL   (China)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

Antipsychotic; Extrapyramidal symptoms; Haloperidol; Risperidone; Schizophrenia

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SYMPTOM; TREATMENT OUTCOME;

EID: 0034761326     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200111000-00002     Document Type: Article

References (32)

1. Structural abnormalities, in the frontal system in schizophrenia: A magnetic resonance imaging study
2. The role of serotonin in schizophrenia
3. Antipsychotic drugs: Is more worse? A meta-analysis of the published randomized control trials
4. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study
5. Risperidone (R 64 766) in the treatment of therapy-resistant chronic psychotic patients: An open dose-finding study
6. Effect of serotonin antagonism in schizophrenia: A pilot study with setoperone
7. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
8. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: A multicentre double-blind comparative study
9. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
10. The two-syndrome concept: Origins and current status
11. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
12. Functional and anatomical aspects of prefrontal pathology in schizophrenia
13. 2 antagonist properties
14. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
15. Serotonin-dopamine interaction and its relevance to schizophrenia
16. The positive-negative distinction in drug-free schizophrenic patients: Stability, response to neuroleptics, and prognostic significance
17. The positive and negative syndrome scale (PANSS) for schizophrenia
18. Reliability and validity of the positive and negative syndrome scale for schizophrenics
19. Serotonergic component of neuroleptic receptors
20. Biochemical profile of risperidone, a new antipsychotic
21. Risperidone in the treatment of schizophrenia
22. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multicentre, double-blind, parallel-group study versus haloperidol
23. The effects of cerebral lesions on intellectual function: A review of current research trends
24. Dopamine receptors and the dopamine hypothesis of schizophrenia
25. Local cooling of prefrontal cortex induces pacemaker-like firing of dopamine neurons in rat central tegmental area in vivo
26. Why do schizophrenic patients refuse to take their drugs?
27. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients
28. Reactions of patients with focal cerebral lesions to success or failure
29. Implications of normal brain development for the pathogenesis of schizophrenia
30. Risperidone in treatment-refractory schizophrenia
31. Negative symptoms and hypofrontality in chronic schizophrenia